News

Researchers have developed a new way to distinguish bradykinin-mediated angioedema from histamine-mediated angioedema. This biomarker tool may improve the use of targeted therapies in angioedema patients. The study, “Threshold‐Stimulated Kallikrein Activity Distinguishes Bradykinin‐ From Histamine‐Mediated Angioedema,” was published in Clinical & Experimental Allergy. Angioedema encompasses…

The U.S. Food and Drug Administration recently approved Shire’s Cinryze (C1 esterase inhibitor [human]) to help prevent angioedema attacks in children 6 and older who live with hereditary angioedema (HAE). Cinryze was first approved in the U.S. in 2008 for routine preventive treatment against attacks in…

A study that examined three forms of angioedema suggests there are different processes contributing to the development of each disease. Researchers found that patients with angioedema of unknown cause have significantly different clinical manifestations compared to patients with hereditary angioedema caused by a genetic deficiency in the C1-inhibitor protein. The…

Delays in the diagnosis of hereditary angioedema causes family caregivers to feel fear, anxiety, and uncertainty, according to a study focused on better understanding what these caregivers go through during the diagnosis process. Giving attention and credibility to family caregivers could not only improve understanding and awareness of the disease but…